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We find that gossypol, a male anti-fertility compound, is a reversible competitive inhibitor of estrogen bind- 
ing to rat a-fetoprotein (AFP). The I(d of gossypol for rat AFP is 1.75 /rM, which is similar to gossypol’s 
affinity for lactate dehydrogenase isozyme X, the putative site where gossypol exerts its anti-fertility effects. 
Reacting sodium cyanoborohydride with gossypol reduces its affinity for AFP, showing that intact aldehyde 
groups on gossypol are important for binding to rat AFP and indicating that gossypol is specifically inter- 
acting with a nucleophilic site on AFP that influences estrogen binding. 
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1. INTRODUCTION 
Gossypol (1,1’,6,6’,7,7’-hexahydroxy-5,5’-dii- 
sopropyl-3,3 ‘-dicarboxyaldehyde) (fig. l), a poly- 
phenolic compound, is the principal pigment in 
cottonseed [l]. There is considerable interest in 
gossypol because it has been successfully used as a 
male contraceptive in large clinical trials in China 
[2-41. The mechanism of action for this male anti- 
fertility effect is still under investigation [3-71. 
I decided to study the effect of gossypol on 
estrogen binding to rat a-fetoprotein (AFP) be- 
cause (1) Philipp and Maripuri (unpublished obser- 
vations) found that gossypol inhibits serine pro- 
teases and (2) previous studies have shown that 
serine protease inhibitors and substrates inhibit 
estrogen binding to rat AFP [8-lo]. Here, I report 
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Fig. 1. Structure of gossypol. The arrows indicate 
aldehyde groups. 
findings which show that gossypol inhibits estro- 
gen binding to rat AFP, and that gossypol’s bin- 
ding to AFP appears to involve interaction with a 
nucleophilic site on AFP. 
2. MATERIALS AND METHODS 
The source of rat a-fetoprotein, serum from 
Buffalo rats with Morris Hepatoma 7777, was a 
gift from Dr Stewart Sell. Gossypol-acetic acid was 
purchased from Sigma. Stock solutions of 10 mM 
gossypol in ethanol at pH 4 were stored at - 20°C. 
Under these conditions gossypol’s binding activity 
for AFP was stable for at least two months. 
For the estrogen binding assay, the serum was 
diluted 1: 100000 into buffer containing 20 mM 
Hepes, 2 mM EDTA, 50 mM NaCl, 20% glycerol 
(HEG buffer) and 0.2 mg/ml ovalbumin. This 
dilution to a final AFP concentration of about 0.5 
nM insures that the AFP concentration is lower 
than both the [3H]estrone ([3H]Er] concentration 
in the binding assay and the equilibrium dissocia- 
tion constant (&) of Er for AFP. Both conditions 
are necessary to obtain interpretable data from our 
experiments [ 111. The competitive binding assay 
was begun by incubating the AFP solution in glass 
tubes on ice with 1 nM [3H]estrone (85-115 
Ci/mmol, New England Nuclear), alone, or with 
gossypol, or with a 300-fold excess of unlabelled 
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estrone for 2 l/2 h. Bound steroid was separated 
from unbound steroid using a dextran-coated char- 
coal technique [9] which involves incubation of 2 
ml sample solution with 0.2 ml of 100 mg/ml char- 
coal, 10 mg/ml dextran, and 5 mg/ml ovalbumin 
for 1 min and then centrifugation at 6000 x g for 15 
min to remove the charcoal. The radioactivity in 1 
ml of supernatant was determined in a liquid scin- 
tillation counter. Specifically bound estrone was 
determined by subtracting the amount of [3H] 
estrone bound in the presence of a 300-fold excess 
concentration of non-radioactive estrone from the 
amount of [‘Hlestrone bound in the absence of the 
non-radioactive estrone. 
3. RESULTS AND DISCUSSION 
Fig. 2 shows that PM concentrations of gossypol 
compete with 1O-9 t3H]estrone (El) for binding to 
rat AFP. A more quantitative determination of 
gossypol’s affinity for rat AFP was obtained using 
competitive Scatchard analysis [ 12,131. The Scat- 
chard graph presented in fig. 3 shows that in the 
presence of gossypol the affinity of [3H]Er binding 
to rat AFP decreases while the maximal number of 
binding sites remains unchanged. This indicates 
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Fig. 2. Competition of gossypol with [‘Hlestrone for rat 
a-fetoprotein. Rat AFP was incubated with 1 x 10m9 M
[3H]E1 alone or with different concentrations of gossyp- 
01, or a 3 x lo-’ M unlabeled estrone at O”C, pH 7.8 for 
2 l/2 h. Then t3H]estrone specifically bound to AFP was 
determined using the dextran-coated charcoal technique. 
Specifically bound estrone in the control sample was 
18 000 cpm/ml. 
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Fig. 3. Scatchard analysis of the effect of 3 x 10v6 M 
gossypol on the binding of [3H]estrone to rat AFP. AFP 
was incubated with [3H]Er (5 x 10-r’ M to 4.5 x 10e9 M) 
+ unlabeled estrone or 3 x 10m6 M gossypol for 2 l/2 h 
at O”C, pH 7.8. Bound steroid was separated from un- 
bound steroid using dextran-coated charcoal. Ordinate: 
specifically bound [3H]estrone (cpm/ml). Abscissa: 
specifically bound [3H]estrone (nM). 
that gossypol is a reversible competitive inhibitor 
of estrogen binding to AFP. 
One can calculate K~OssypO1, the equilibrium 
dissociation constant of gossypol for rat AFP, 
from the equation: 
K$3SSyPd = Kdc 
Kdapp - & 
where Kd is the equilibrium dissociation constant 
of [3H]Er for rat AFP, Kdpp is the apparent 
equilibrium dissociation constant of [3H]Ei in the 
presence of gossypol, and C is the gossypol con- 
centration [13]. This equation gives an upper limit 
on KijoSSYPOl because the gossypol concentration 
may be less than the nominal concentration due to 
factors such as association of gossypol with other 
proteins and decomposition of gossypol during the 
binding assay. Using that equation we find that 
K$‘ssypO’ for rat AFP is 1.75 PM (table 1). 
Authors in [7] suggested that gossypol acts by 
selectively inhibiting the lactate dehydrogenase 
(E.C.l.l .1.27) isozyme X (LDH X), which plays 
an important role in sperm metabolism. Consistent 
with the need for high concentrations of gossypol 
(20 mg/day) to achieve contraception [2-41, the Ki 
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Table 1 
Effect of gossypol on estrone binding to rat 
a-fetoprotein 
Condition Kd (M) K~ypO* (M) 
[3H]estrone (n = 7) 8 x lo-” 
+ 3 x 1O-6 M gossypol 21.7 x lo-” 1.75 x 1O-6 
(n=7) 
n = number of experients 
of gossypol for LDH X is between 2-5 ,uM [7,14]. 
This affinity is comparable to that of gossypol for 
rat AFP (table 1) and for human testosterone-es- 
trogen binding globulin (unpublished). This raises 
the possibility that in bioassays gossypol may be 
inhibiting the binding of steroid hormones to 
proteins. 
Are aldehyde groups on gossypol important in 
its binding to AFP? A reason for thinking that 
the aldehyde groups on gossypol would be impor- 
tant for its binding to AFP comes from a hypo- 
thesis based on the observation that AFP contains 
a site that both recognizes serine protease inhibit- 
ors and substrates and influences estrogen binding 
[8-lo]. This hypothesis, that rat AFP contains a 
nucleophilic (electron-rich) site that influences 
estrogen binding by interacting with electrophilic 
sites on steroids and/or with proton donors on rat 
AFP, predicts that the electrophilic (electron- 
deficient) aldehyde groups on gossypol (fig. 1) 
would be important for its binding to rat AFP [ 151. 
To test this hypothesis we incubated gossypol with 
Table 2 
Incubation of gossypol with sodium cyanoborohydride 
decreases gossypol’s affinity for rat cu-fetoprotein 
Condition Specifically bound [3H]Er 
(cpm/ml) 
Control 
+ 5 /zM gossypol 
+ 5 ,uM gossypol treated 
with NaBGsCN 
16560 
5 620 
12240 
A solution of 10 mM gossypol acetic acid in ethanol (pH 
4) and 10 mM sodium cyanoborohydride was incubated 
for 30 min at 22°C. Then the NaBHxCN concentration 
was increased to 20 mM and the incubation continued 
for 6 h at 22°C. Treated and untreated gossypol were 
tested for their ability to inhibit [3H]Er binding to rat 
AFP as described in section 2. 
the reducing agent sodium cyanoborohydride 
(NaBHKN) a chemical that selectively converts 
aldehyde groups to alcohols 1161. Table 2 shows 
that incubation of gossypol with NaBH3CN 
significantly reduced gossypol’s affinity for rat 
AFP supporting this hypothesis. This finding sug- 
gests that: (1) inhibition of [3H]Er binding to AFP 
by gossypol involves a specific interaction between 
gossypol and rat AFP rather than being due to 
nonspecific hydrophobic partitioning of gossypol 
into AFP, and (2) changing the electrophilicity of 
sites on gossypol may prove useful in regulating its 
binding to AFP. 
Concerning the latter possibility, two modifica- 
tions that could increase the electrophilicity of the 
aldehyde groups would be substituting either a 
nitro group for the isopropyl group or a ring 
nitrogen para to the aldehyde group. There is 
precedence for these modifications to increase the 
aldehyde group’s electrophilicity in the chemistry 
of pyridoxal phosphate [ 171. 
Gossypol appears to have minimal side effects!. 
This suggests an interesting and unexpected ap- 
plication of this work, the use of gossypol and 
possibly the gossypol analogues described above to 
study the function of AFP in rats and mice, includ- 
ding male rats with AFP-secreting hepatomas. 
Also, it will be important to find out if 
‘NaBHjCN-treated’ gossypol possesses contracep- 
tive activity, anti-herpes activity [18], or if it in- 
hibits lactate dehydrogenase isozyme X [7], serine 
enzymes, or the growth of Trypanosoma cruzi 
[14]. If reduced gossypol is ineffective in those 
assays, then the previously described gossypol 
analogues may have application in those systems. 
While this research was being completed, it was 
reported [ 191 that gossypol bound to human serum 
albumin with high affinity (Kd- lo-’ M) at the 
bilirubin binding site. The effect of NaBH3CN 
treatment of gossypol on its binding to albumin 
was not studied. The presence of a site that binds 
gossypol on both albumin and AFP might be ex- 
pected, since AFP is thought to have evolved by a 
duplication of the albumin gene [20-221, and both 
proteins have some ligand binding properties in 
common, including binding bilirubin [23-261. 
However, the report [26] that bilirubin does not in- 
hibit estrogen binding to AFP suggests that there 
are differences between AFP and albumin in their 
binding of gossypol. 
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